Submit to Cancers Review for Cancers Propose a Special Issue

Journal Browser

► Journal Browser

Gastric-Type Mucinous Carcinoma (GAS) of the Uterine Cervix 2.0

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (15 April 2023) | Viewed by 6012

Share This Special Issue

Special Issue Editor

Dr. Shin Nishio

E-Mail Website
Guest Editor

Department of Obstetrics and Gynecology, Kurume University School of Medicine, Fukuoka 830-0011, Japan
Interests: cervical cancer; endometrial cancer; ovarian cancer; rare tumor; chemotherapy; clinical trial

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of the previous release, “Gastric-Type Mucinous Carcinoma (GAS) of the Uterine Cervix” (https://www.mdpi.com/journal/cancers/special_issues/GAS_Cancers).

Gastric-type mucinous carcinoma (GAS) of the uterine cervix is a relatively newly recognized variant of endocervical adenocarcinoma. GAS was initially described by Japanese groups and was included as a subtype of endocervical mucinous adenocarcinoma in the World Health Organization classification (WHO) in 2014. It is defined as a mucinous carcinoma with gastric-type differentiation and includes minimal deviation adenocarcinoma (MDA), also known as adenoma malignum, due to its morphologic spectrum. GAS has a poorer prognosis than usual-type endocervical adenocarcinomas (UEAs), is resistant to conventional treatments, and urgently requires new treatments. However, the molecular mechanisms leading to its development are not well known. In recent years, several studies have reported the biological features of GAS based on its genetic background. In this Special Issue, we will focus on the latest research in GAS.

Dr. Shin Nishio
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

GAS
clinicopathological factor
genetic analysis
gene expression
therapy

Published Papers (3 papers)

Download All Papers

Research

Jump to: Review

12 pages, 635 KiB

Open AccessArticle

Poor Treatment Outcomes of Locally Advanced Cervical Adenocarcinoma of Human Papilloma Virus Independent Type, Represented by Gastric Type Adenocarcinoma: A Multi-Center Retrospective Study (Sankai Gynecology Study Group)

by Toshiyuki Seki, Atsumi Kojima, Shinichi Okame, Satoshi Yamaguchi, Aikou Okamoto, Hideki Tokunaga, Shin Nishio, Yuji Takei, Yoshihito Yokoyama, Manabu Yoshida, Norihiro Teramoto, Yoshiki Mikami, Muneaki Shimada, Junzo Kigawa and Kazuhiro Takehara

Cancers 2023, 15(6), 1730; https://doi.org/10.3390/cancers15061730 - 12 Mar 2023

Cited by 1 | Viewed by 1753

Abstract

The revised World Health Organization classification of cervical cancer divides adenocarcinomas into human papillomavirus-associated (HPVa) and -independent (HPVi) types; the HPVi type is represented by the gastric type. The treatment outcomes of locally advanced adenocarcinoma (LaAC), based on this classification, are understudied. We investigated the outcomes of patients with HPVa and HPVi LaACs. Data for all consecutive patients with stage IB3 to IIIC1 adenocarcinoma who received treatment at 12 institutions throughout Japan between 2004 and 2009 were retrieved to analyze progression-free and overall survival. Central pathological review classified 103 and 48 patients as having HPVa and HPVi tumors, respectively. Usual- (84%) and gastric- (90%) type adenocarcinomas were the most frequent subtypes. Surgery was the primary treatment strategy for most patients. Progression-free and overall survival of patients with HPVi were worse than those of patients with HPVa (p = 0.009 and 0.032, respectively). Subgroup analysis by stage showed that progression-free survival was significantly different for stage IIB. The current surgical treatment strategy for LaACs is less effective for HPVi tumors than for HPVa tumors, especially those in stage IIB. Full article

(This article belongs to the Special Issue Gastric-Type Mucinous Carcinoma (GAS) of the Uterine Cervix 2.0)

► Show Figures

Figure 1

12 pages, 1271 KiB

Open AccessArticle

Gastric-Type Adenocarcinoma of the Uterine Cervix Associated with Poor Response to Definitive Radiotherapy

by Airi Kuruma, Michiko Kodama, Yumiko Hori, Kazuaki Sato, Makoto Fujii, Fumiaki Isohashi, Ai Miyoshi, Seiji Mabuchi, Akira Setoguchi, Hiroko Shimura, Takeshi Goto, Aska Toda, Satoshi Nakagawa, Yasuto Kinose, Tsuyoshi Takiuchi, Eiji Kobayashi, Kae Hashimoto, Yutaka Ueda, Kenjiro Sawada, Eiichi Morii and Tadashi Kimura Show full author list Hide full author list

Cancers 2023, 15(1), 170; https://doi.org/10.3390/cancers15010170 - 28 Dec 2022

Cited by 4 | Viewed by 2210

Abstract

We aimed to evaluate the response to definitive radiotherapy (RT) for cervical cancer based on histological subtypes and investigate prognostic factors in adenocarcinoma (AC). Of the 396 patients treated with definitive RT between January, 2010 and July, 2020, 327 patients met the inclusion criteria, including 275 with squamous cell carcinoma (SCC) and 52 with AC restaged based on the 2018 International Federation of Gynecology and Obstetrics staging system. Patient characteristics, response to RT, and prognoses of SCC and AC were evaluated. The complete response (CR) rates were 92.4% and 53.8% for SCC and AC, respectively (p < 0.05). Three-year overall survival and progression-free survival (PFS) rates of SCC were significantly higher than those of AC (88.6% vs. 74.1%, p < 0.05 and 76.3% vs. 59.3%, p < 0.05, respectively). Among the AC population, univariate and multivariate analyses were performed to examine prognostic factors associated with non-complete response (CR). In the multivariate analysis, gastric-type adenocarcinoma (GAS) was associated with non-CR in AC (adjusted odds ratio, 12.2; 95% confidence interval 1.0–145.6; p < 0.05). The 3-year PFS rate in patients with GAS was significantly lower than that in patients with other histological types of AC (44.4% vs. 66.7%, p < 0.05). Definitive RT for cervical cancer was significantly less effective for AC than for SCC. GAS was the only independent prognostic factor associated with non-CR in AC. Full article

(This article belongs to the Special Issue Gastric-Type Mucinous Carcinoma (GAS) of the Uterine Cervix 2.0)

► Show Figures

Figure 1

Review

Jump to: Research

12 pages, 9471 KiB

Open AccessReview

Fertility Sparing Treatment in Gastric-Type Endocervical Carcinoma

by Agnieszka Rychlik, Denis Querleu and Mariusz Bidzinski

Cancers 2021, 13(20), 5177; https://doi.org/10.3390/cancers13205177 - 15 Oct 2021

Cited by 3 | Viewed by 1626

Abstract

Fertility sparing management of cancer is one of the main components of quality-of-life issues. Early-stage cervical cancer, frequently diagnosed in women of reproductive age, can potentially be treated conservatively. However, some rare histological types of cervical cancer present with aggressive clinical behavior. Particularly, in the newly introduced concept of gastric-type endocervical carcinoma, fertility sparing management is ‘a priori’ not recommended. Even so, this issue remains undocumented. For this reason, a selected review of the current literature on gastric type endocervical carcinoma was carried out through PubMed. The keywords included “gastric-type cervical cancer”, “gastric-type endocervical carcinoma”, “conservative surgery”, “conservative treatment”, “fertility sparing surgery”, “radical trachelectomy”, “laparoscopic trachelectomy”, “robotic trachelectomy”, “laparotomic trachelectomy”, “abdominal trachelectomy”, “trachelectomy”, “neoadjuvant chemotherapy”, “conisation”, and “cone resection”. A search in the European Network on Cancer, Infertility and Pregnancy (INCIP) database was performed. The rarity of gastric-type endocervical carcinoma does not allow for conclusions on fertility sparing management with solid evidence. However, diffuse character of the disease and aggressive clinical behavior contraindicate a conservative treatment in young women with gastric type cervical cancer. Full article

(This article belongs to the Special Issue Gastric-Type Mucinous Carcinoma (GAS) of the Uterine Cervix 2.0)

► Show Figures